Josh H. Lei

Sar, 999078, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

GSDME mediated pyroptosis drives CCL5 secretion and dictates proteasome inhibitor efficacy in solid tumors.

GSDME mediated pyroptosis drives CCL5 secretion and dictates proteasome inhibitor efficacy in solid tumors.

Journal: Pharmacological research

Published: April 24, 2026

A miniaturized-tumor culture platform for developing anti-tumor immunotherapies.

A miniaturized-tumor culture platform for developing anti-tumor immunotherapies.

Journal: Theranostics

Published: January 26, 2026

Correction to "Photocatalytic Pt(IV)-Coordinated Carbon Dots for Precision Tumor Therapy".

Correction to "Photocatalytic Pt(IV)-Coordinated Carbon Dots for Precision Tumor Therapy".

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 05, 2025

Dasatinib Inhibits Basal B Breast Cancer Through ETS1-Mediated Extracellular Matrix Remodeling.

Dasatinib Inhibits Basal B Breast Cancer Through ETS1-Mediated Extracellular Matrix Remodeling.

Journal: Biomedicines

Published: September 18, 2025

Proteasome: Role in T Cell Function Regulation.

Proteasome: Role in T Cell Function Regulation.

Journal: International journal of biological sciences

Published: September 12, 2025

Tumor cell intrinsic dsRNA innate immune response triggered by PARP inhibitor is compromised in BRCA1-deficient breast cancer by repressing IRF3.

Tumor cell intrinsic dsRNA innate immune response triggered by PARP inhibitor is compromised in BRCA1-deficient breast cancer by repressing IRF3.

Journal: Protein & cell

Published: July 03, 2025

RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.

RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.

Journal: Cell death & disease

Published: May 10, 2025

Proteasomes suppress anticancer drug-induced cytotoxicity by inhibiting mitochondrial protein import and promoting ROS-BNIP3-mediated mitophagy.

Proteasomes suppress anticancer drug-induced cytotoxicity by inhibiting mitochondrial protein import and promoting ROS-BNIP3-mediated mitophagy.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: April 08, 2025

α9 Nicotinic Acetylcholine Receptor Promotes Tumor Proliferation and Suppresses Ferroptosis in Triple-Negative Breast Cancer.

α9 Nicotinic Acetylcholine Receptor Promotes Tumor Proliferation and Suppresses Ferroptosis in Triple-Negative Breast Cancer.

Journal: Biomolecules

Published: March 04, 2025

Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy.

Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy.

Journal: Cell death & disease

Published: February 02, 2025

Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer.

Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer.

Journal: Cell reports. Medicine

Published: December 13, 2024

Alkaline Adjuvant Regulates Proteolytic Activity of Macrophages for Antigen Cross-Presentation and Potentiates Radioimmunotherapy.

Alkaline Adjuvant Regulates Proteolytic Activity of Macrophages for Antigen Cross-Presentation and Potentiates Radioimmunotherapy.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: October 30, 2024

Showing 1-12 of 37

Last Updated: 09/26/2026